SG3 Management’s Karyopharm Therapeutics KPTI Stock Holding History

SG3 Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,667	Closed	-$166K	–	1175
2021 Q3	$146K	Buy	+1,667	New	+$173K	﹤0.01%	819
2020 Q3	–	Sell	-333	Closed	-$95K	–	984
2020 Q2	$95K	Buy	+333	New	+$98.5K	0.01%	537

Other funds holding KPTI

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

SG3 Management's KPTI Position: Q4 2021 in Review

SG3 Management sold out of Karyopharm Therapeutics (KPTI) in Q4 2021, closing a stake of 1,667 shares — an estimated $166K sold.

SG3 Management first reported a position in KPTI in Q2 2020 and held it in 2 quarters. The position peaked at $146K in Q3 2021. 143 funds tracked by Wall St. Rank hold KPTI as of Q4 2021.

SG3 Management reported no remaining Karyopharm Therapeutics position as of Q4 2021 after selling out during the quarter.
SG3 Management sold 1,667 Karyopharm Therapeutics shares in Q4 2021, an estimated $166K.
SG3 Management first reported a position in Karyopharm Therapeutics in Q2 2020 and held it in 2 quarters.
SG3 Management's Karyopharm Therapeutics position peaked at $146K in Q3 2021.
143 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2021.

Based on SG3 Management's 13F filing for Q4 2021, filed 15 Feb 2022.